Parabilis Medicines, Inc. (NASDAQ:PBLS – Free Report) – Analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Parabilis Medicines in a research report issued on Thursday, October 22nd. HC Wainwright analyst R. Burns expects that the company will earn ($0.35) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Parabilis Medicines’ current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Parabilis Medicines’ Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($2.10) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.55) EPS.
Several other analysts have also recently weighed in on the stock. Bank of America began coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They issued a “buy” rating and a $45.00 target price on the stock. Leerink Partners initiated coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set an “outperform” rating and a $40.00 price target for the company. Lifesci Capital raised shares of Parabilis Medicines to a “strong-buy” rating in a research report on Monday, July 6th. Evercore started coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating on the stock. Finally, Guggenheim started coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They set a “buy” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Parabilis Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $41.25.
Parabilis Medicines Stock Performance
PBLS stock opened at $25.03 on Monday. The stock’s 50 day moving average price is $34.11. Parabilis Medicines has a fifty-two week low of $22.66 and a fifty-two week high of $42.49.
Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $0.15 million during the quarter.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC purchased a new stake in Parabilis Medicines during the third quarter worth approximately $35,000. WINTON GROUP Ltd acquired a new position in Parabilis Medicines in the second quarter valued at $955,000. Squarepoint Ops LLC acquired a new stake in shares of Parabilis Medicines in the 2nd quarter valued at about $1,327,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Parabilis Medicines in the second quarter valued at approximately $52,572,000. Finally, ICONIQ Capital LLC acquired a new stake in Parabilis Medicines during the 2nd quarter worth $9,580,000.
About Parabilis Medicines
Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.
Recommended Stories
- Five stocks we like better than Parabilis Medicines
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
